The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 12, 2022

Filed:

Jun. 18, 2018
Applicant:

Kindred Biosciences, Inc., Burlingame, CA (US);

Inventors:

Shyr Jiann Li, Millbrae, CA (US);

Lam Nguyen, Union City, CA (US);

Lan Yang, Burlingame, CA (US);

Hangjun Zhan, Foster City, CA (US);

Assignee:

Kindred Biosciences, Inc., Burlingame, CA (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07K 16/24 (2006.01); A61K 39/395 (2006.01); C12N 15/63 (2006.01); C12N 5/10 (2006.01); C07K 14/755 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/244 (2013.01); A61K 39/3955 (2013.01); C12N 15/63 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01);
Abstract

Provided are various embodiments relating to anti-IL17A antibodies and IL17Ra ECD polypeptides that bind to IL17A. In various embodiments, such anti-IL17A antibodies or IL17Ra ECD polypeptides can be used in methods to treat IL17-induced conditions in subjects, such as humans or companion animals, such as canines, felines, and equines. Also provided are various embodiments relating to IgG Fc variant polypeptides having one or more amino acid substitutions for reducing binding to C1q and/or CD16. In some embodiments, the IgG Fc variants and/or polypeptides comprising the IgG Fc variants (e.g., fusion polypeptides comprising the IgG Fc variants and the anti-IL17A antibodies and/or IL17Ra ECD polypeptides described herein) may have reduced complement-mediated immune responses and/or antibody-dependent cell-mediated cytotoxicity.


Find Patent Forward Citations

Loading…